MAP
IART icon

Madison Avenue Partners’s Integra LifeSciences IART Stock Holding History

Madison Avenue Partners’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,042,156
Closed -$45.4M – 20
2023
Q4 		$45.4M Buy
1,042,156
+77,489
+8% +$3.05M 6.41% 5
2023
Q3 		$36.8M Buy
964,667
+40,000
+4% +$1.68M 5.23% 5
2023
Q2 		$38M Buy
+924,667
New +$44.5M 8.3% 5

Other funds holding IART

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Madison Avenue Partners's IART Position: Q1 2024 in Review

Madison Avenue Partners sold out of Integra LifeSciences (IART) in Q1 2024, closing a stake of 1,042,156 shares — an estimated $45.4M sold.

Madison Avenue Partners first reported a position in IART in Q2 2023 and held it in 3 quarters. The position peaked at $45.4M in Q4 2023. 281 funds tracked by Wall St. Rank hold IART as of Q1 2024.

  • Madison Avenue Partners reported no remaining Integra LifeSciences position as of Q1 2024 after selling out during the quarter.
  • Madison Avenue Partners sold 1,042,156 Integra LifeSciences shares in Q1 2024, an estimated $45.4M.
  • Madison Avenue Partners first reported a position in Integra LifeSciences in Q2 2023 and held it in 3 quarters.
  • Madison Avenue Partners's Integra LifeSciences position peaked at $45.4M in Q4 2023.
  • 281 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2024.

Based on Madison Avenue Partners's 13F filing for Q1 2024, filed 15 May 2024.